GoodRx reports that step therapy requires patients to try lower-cost medications before coverage for prescribed treatments.

Kivo reports that quality control significantly drives up prescription costs by ensuring safety and compliance in the pharmaceutical industry.

The thriving market in online, counterfeit GLP-1 drugs that do not meet FDA criteria poses serious risks to consumers.

GoodRx reports on how to handle situations when medications aren't covered by insurance, offering tips for appeals, alternatives, and financial assistance.

The recall potentially affects more than 1 million people. It is the second time the FDA has found sterility issues at the company in three years.

Kivo reports that the journey of prescription drugs involves extensive research, clinical trials, regulatory reviews, and global supply chains.

The reasons are not fully understood, but changes in the gut microbiome are believed to play a role.

Ivim Health reports that peptide therapies, spurred by GLP-1 interest, require careful understanding and medical oversight for safe use.

Black patients were less likely to receive higher doses. This may reflect inequities in health care or misconceptions among patients that higher doses are unsafe.

Kivo reports that new drug access varies by state, with delays ranging from two to five months after FDA approval, impacting patient care.